Alpine Immune Sciences - ALPN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 191.67 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.20
▲ +0.03 (0.42%)

This chart shows the closing price for ALPN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alpine Immune Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALPN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALPN

Analyst Price Target is $21.00
▲ +191.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alpine Immune Sciences in the last 3 months. The average price target is $21.00, with a high forecast of $25.00 and a low forecast of $17.00. The average price target represents a 191.67% upside from the last price of $7.20.

This chart shows the closing price for ALPN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Alpine Immune Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/15/2022WedbushBoost Target$25.00Low
5/17/2022WedbushReiterated RatingOutperform$22.00Low
5/13/2022HC WainwrightReiterated RatingBuy$21.00Medium
3/7/2022OppenheimerLower Target$19.00 ➝ $17.00High
6/24/2021HC WainwrightReiterated RatingBuy$21.00Medium
6/3/2021HC WainwrightReiterated RatingBuy$21.00High
3/19/2021OppenheimerReiterated RatingBuy$19.00High
12/21/2020HC WainwrightInitiated CoverageBuy$21.00Low
8/26/2020CowenInitiated CoverageOutperformLow
8/12/2020OppenheimerReiterated RatingBuy$19.00High
8/11/2020Piper SandlerLower TargetOverweight$21.00 ➝ $18.00High
6/19/2020Piper SandlerBoost Target$8.00 ➝ $21.00Low
6/19/2020WedbushBoost TargetOutperform$10.00 ➝ $22.00Low
6/8/2020OppenheimerReiterated RatingBuy$12.00High
5/26/2020WedbushReiterated RatingOutperform$10.00Medium
5/26/2020LADENBURG THALM/SH SHReiterated RatingBuy$17.00Medium
5/26/2020Piper SandlerReiterated RatingOverweight$8.00Medium
5/14/2020OppenheimerReiterated RatingBuy$12.00High
3/31/2020WedbushReiterated RatingOutperformMedium
11/13/2019Piper Jaffray CompaniesLower TargetOverweight$8.00Low
3/19/2019OppenheimerSet TargetBuy$13.00Low
12/3/2018OppenheimerSet TargetBuy$13.00Low
11/12/2018OppenheimerSet TargetBuy$13.00High
9/27/2018Piper Jaffray CompaniesInitiated CoverageOverweight$12.00High
8/13/2018Raymond JamesInitiated CoverageBuy$13.00High
6/29/2018OppenheimerInitiated CoverageOutperform$13.00High
6/28/2018CitigroupInitiated CoverageOutperform$13.00High
5/17/2018WedbushInitiated CoverageOutperform$13.00High
(Data available from 10/1/2017 forward)

News Sentiment Rating

1.29 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/5/2022
  • 7 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
4/4/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/3/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 9 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022

Current Sentiment

  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Alpine Immune Sciences logo
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $7.20
Low: $7.10
High: $7.38

50 Day Range

MA: $8.02
Low: $6.89
High: $8.90

52 Week Range

Now: $7.20
Low: $6.00
High: $14.40

Volume

136,588 shs

Average Volume

136,382 shs

Market Capitalization

$218.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Alpine Immune Sciences?

The following Wall Street sell-side analysts have issued reports on Alpine Immune Sciences in the last twelve months: HC Wainwright, Oppenheimer Holdings Inc., and Wedbush.
View the latest analyst ratings for ALPN.

What is the current price target for Alpine Immune Sciences?

3 Wall Street analysts have set twelve-month price targets for Alpine Immune Sciences in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 191.7%. Wedbush has the highest price target set, predicting ALPN will reach $25.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $17.00 for Alpine Immune Sciences in the next year.
View the latest price targets for ALPN.

What is the current consensus analyst rating for Alpine Immune Sciences?

Alpine Immune Sciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALPN will outperform the market and that investors should add to their positions of Alpine Immune Sciences.
View the latest ratings for ALPN.

What other companies compete with Alpine Immune Sciences?

How do I contact Alpine Immune Sciences' investor relations team?

Alpine Immune Sciences' physical mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company's listed phone number is (206) 788-4545 and its investor relations email address is [email protected] The official website for Alpine Immune Sciences is www.alpineimmunesciences.com. Learn More about contacing Alpine Immune Sciences investor relations.